Mechanism of Action of a Potent Antiplatelet Peptide, Triflavin from Trimeresurus flavoviridis Snake Venom

Summary

Triflavin, an antiplatelet peptide from Trimeresurus flavoviridis snake venom, inhibits aggregation of human platelets stimulated by a variety of agonists. However, triflavin does not affect the shape change and release reaction of platelets stimulated by thrombin and collagen. In this paper, we further investigate its effect on the intracellular events occurring after the activation of platelets. Triflavin does not inhibit the intracellular free calcium rise of Quin 2-AM loaded platelets stimulated by thrombin and it also has no significant effect on thromboxane B₂ formation of platelets stimulated by thrombin. Triflavin does not affect the ³(H)-inositol monophosphate formation of the ³(H)-myoinositol loaded platelets. However, triflavin dose-dependently inhibits fibrinogen-induced aggregation and ¹²⁵I-fibrinogen binding of ADP-stimulated platelets. In addition, triflavin dose-dependently blocks fibrinogen-induced aggregation of elastase-treated platelets. It is concluded that triflavin specifically inhibits fibrinogen binding to fibrinogen receptors associated with glycoprotein IIb/IIIa complex on platelet membrane surface without any inhibitory effect on the platelet-activation process.

• References

• 1 Bennet JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64: 1393-401
• 2 Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979; 254: 5357-63
• 3 Ruggeri ZM, Bader R, de Marco L. Glanzmann's thrombasthenia: Deficient binding of von Willebrand factor to thrombin-stimulated platelets. Proc Natl Acad Sci USA 1982; 79: 6038-41
• 4 Peerschke EI, Zucker MB, Grant RA, Egan JJ, Johnson MM. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood 1980; 55: 841-7
• 5 Nachman RL, Leung LLK. Complex formation of platelet membrane Glycoproteins IIb and IIIa with fibrinogen. J Clin Invest 1982; 69: 263-9
• 6 Gogstad GO, Brosstad F, Krutnes MB, Hagen I, Solum NO. Fibrinogen-binding properties of the human platelet Glycoprotein IIb-IIIa complex: A study using crossed-radioimmunoelectrophoresis. Blood 1982; 60: 663-71
• 7 Berridge MJ. Inositol trisphosphate and diacylglycerol as second messengers. Biochem J 1984; 220: 345-60
• 8 Hokin L. Receptors and phosphoinositide-generated second messengers. Annu Rev Biochem 1985; 54: 205-35
• 9 Majerus PW, Wilson DB, Connolly TM, Bross TE, Neufeld EJ. Phosphoinositide turnover provides a link in stimulus-response coupling. Trends Biochem Sci 1985; 10: 168-70
• 10 Detwiler TC, Charo IF, Feinman RD. Evidence that calcium regulates platelet function. Thromb Haemostas 1978; 40: 207-11
• 11 Feinstein MB, Rodan GA, Cutler LS. In: Platelets in Biology and Pathology. Gordon JL. (ed) Vol 2. Elsevier Biomedical, Amsterdam: 1981
• 12 Brass LF, Joseph SK. A role for inositol trisphosphate in intracellular Ca²⁺ mobilization and granule secretion in platelets. J Biol Chem 1985; 260: 1572-9
• 13 Authi KS, Evenden BJ, Crawford N. Metabolic and functional consequences of introducing inositol 1,4,5-trisphosphate into saponinpermeabilized human platelets. Biochem J 1985; 233: 709-18
• 14 Huang TF, Sheu JR, Teng CM. A potent antiplatelet peptide, Triflavin, from Trimeresurus flavoviridis snake venom. Biochem J 1991 277. (in press)
• 15 Ouyang C, Huang TF. Potent platelet aggregation inhibitor from Trimeresurus gramineus snake venom. Biochim Biophys Acta 1983; 757: 332-41
• 16 Huang TF, Holt JC, Lukasiewicz H, Niewiarowoski S. Trigramin, a low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb/IIIa complex. J Biol Chem 1987; 262: 16157-63
• 17 Huang TF, Holt JC, Kirby EP, Niewiarowski S. Trigramin: Primary structure and its inhibition of von Willebrand factor binding to glycoprotein IIb/IIIa complex on human platelets. Biochemistry 1989; 28: 661-6
• 18 Gan ZR, Gorild RJ, Jacobs JW, Friedman PA, Polokoff MA. Echistatin, a potent platelet aggregation inhibitor from the venom of viper, Echis carinatus. . J Biol Chem 1988; 263: 19827-19832
• 19 Dennis MS, Henzel WJ, Pitti RM, Lipari MT, Napier MA, Deisher TA, Bunting S, Lazarus RA. Platelet glycoprotein IIb/IIIa protein antagonists from snake venom: Evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci USA 1989; 87: 2471-5
• 20 Huang TF, Sheu JR, Teng CM, Chen SW, Liu CS. Triflavin, an antiplatelet Arg-Gly-Asp-containing peptide, is a specific antagonist of platelet membrane glycoprotein IIb/IIIa complex. J Biochem 1991; 109: 328-34
• 21 Mustard JF, Perry DW, Ardlie NG, Packham MA. Preparation of suspensions of washed platelets from humans. Br J Haematol 1972; 22: 193-204
• 22 Kornecki E, Niewiarowski S, Morinelli TA, Kloczewiak M. Effects of chymotrypsin and adenosine diphosphate on the exposure of fibrinogen receptors on normal human and Glanzmann's thrombasthenic platelets. J Biol Chem 1981; 256: 5696-701
• 23 Kornecki E, Ehrlich YH, De Mars DD, Lenox RH. Exposure of fibrinogen receptors in human platelets by surface proteolysis with elastase. J Clin Invest 1986; 77: 750-6
• 24 Rink TJ, Pozzan T. Using quin 2 in cell suspension. Cell Calcium 1985; 6: 133-44
• 25 Berridge MJ. Rapid accumulation of inositol trisphosphate reveals that agonists hydrolyse polyphospoinositides instead of phosphatidy-linositol. Biochem J 1983; 212: 249-58
• 26 Neylon CB, Summers RJ. Stimulation of ₁-adrenoceptors in rat kidney mediates increased inositol phospholipid hydrolysis. Br J Pharmacol 1987; 91: 367-76
• 27 Lipinska I, Lipinski B, Gurewich V. Fibrinogen heterogeneity in human plasma. Electrophoretic demonstration and characterization of two major fibrinogen compounds. J Lab Clin Med 1974; 84: 509-16
• 28 Niewiaroswki S, Budzynski AZ, Morinelli TA, Brudzynski TM, Stewart GJ. Exposure of fibrinogen receptor on human platelets by proteolytic enzyme. J Biol Chem 1981; 256: 917-25
• 29 Scatchard G. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 1949; 51: 660-72
• 30 Greenberg K, Or JL, Packham MA, Guccione MA, Harfenist EJ, Kinlough-Rathbone RL, Perry DM, Mustard JF. The effects of pretreatment of human or rabbit platelets with chymotrypsin on their responses to human fibrinogen and aggregating agents. Blood 1979; 54: 753-65
• 31 Charo IF, Feinman RD, Detwiler TC. Inhibition of platelet secretion by an antagonist of intracellular calcium. Biochem Biophys Res Commun 1976; 72: 1462-7
• 32 Bell RL, Kennerly DA, Stanford N, Majerus PW. Diglyceride lipase: A pathway for arachidonic acid release from human platelets. Proc Natl Acad Sci USA 1979; 76: 3238-43
• 33 Mckean ML, Smith JB, Silver WJ. Formation of lysophosphatidylcholine in human platelets in response to thrombin. J Biol Chem 1981; 256: 1522-4
• 34 Weiss HJ. (ed) Platelets: Pathophysiology and Antiplatelet Drug Therapy. Alan R. Liss, Inc., New York: 1983. p 46
• 35 Abdel-Latif AA, Akhlar R, Hawthorne JN. Acetylcholine increase the breakdown of triphosphoinositide of rabbit iris muscle prelabelled with (³²P)phosphate. Biochem J 1977; 162: 61-73
• 36 Kirk CJ, Creba JA, Downes CP, Michell RH. Hormone-stimulated metabolism of inositol lipids and its relationship to hepatic receptor function. Biochem Soc Trans 1981; 9: 377-9
• 37 Knudsen KA, Tuszynski GF, Huang TF, Niewiarowski S. Trigramin, an RGD-containing peptide from snake venom, inhibits cell-sub-stratum adhesion of human melanoma cells. Exp Cell Res 1988; 179: 42-9